InspireMD Announces Distribution Agreement for MGuard Prime in Chile
TEL AVIV, ISRAEL - (NewMediaWire) - October 12, 2017 - InspireMD, Inc. (NYSE American: NSPR) (NYSE MKT: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with CorpMedical Chile Ltda, a leading medical distributor in Chile, with its headquarters in Santiago de Chile, to distribute the MGuard Prime™ Embolic Protection System (EPS) for the treatment of acute coronary syndromes, namely Acute Myocardial Infarctions (AMI).
Mr. Jaime Kehr, Chief Executive Officer of CorpMedical Chile Ltda, noted, "MGuard Prime™ with its MicroNet™ technology is a very effective treatment option in STEMI (ST segment elevation in myocardial infarction) patients in the presence of high thrombotic content and in patients with Saphenous Vein Grafts as seen in clinical trials evaluating MGuard. MGuard is the only implant device available in the market we are aware of that offers protection against embolization following stenting in patients with acute myocardial infarction. Given the safety advantages of MGuard™ Prime, supported by positive clinical data demonstrating its ability to significantly reduce the incidence of no-reflow syndrome and its associated risk of increased mortality, we look forward to bringing this technology to market in Chile."
Agustin Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are excited to partner with CorpMedical Chile Ltda., which brings long standing relationships with key opinion leaders in Chile. With a population of more than 17 million people, Chile represents an attractive new growth opportunity and will help further expand our presence in Latin America."
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.